Hemodialysis ComplicationNCT05887960
Impact of Neutrophil Lymphocyte and Monocyte Lymphocyte Ratio on Chronic Kidney Disease Patients Outcome
An observational study of Hemodialysis Complication, run by Assiut University.
Trial summary
The aim of this study is to establish NLR, MLR as a good predictors for outcome of CKD including hemodialysis and CKD stage (4-5) patients as regard inflammation, malnutrition and anemia on cardiovascular complication. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Hemodialysis Complication
- What is being tested?
- CBC and flow cytometry test for monocyte
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2023to Oct 2024
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: healthy persons as control group patients with chronic kidney disease (CKD) stage 4-5 (not on dialysis) patients ESRD on maintenance hemodialysis
Who may be able to join
- - Hemodialysis patients > 18 years
- < 60 years old
- CKD stage (4-5) not on dialysis
Who cannot join
- o Recent acute coronary or cerebrovascular accident
- Autoimmune diseases
- Hematological diseases
- Liver cirrhosis
- Active or pre-active infection
- Malignancy
- Medications as Aspirin, NSAI, immunosuppressive steroid.
Trial locations and contacts
No sites are listed yet.
Samir KM Abdelhamid, professor contact
About this study
The aim of this study is to establish NLR, MLR as a good predictors for outcome of CKD including hemodialysis and CKD stage (4-5) patients as regard inflammation, malnutrition and anemia on cardiovascular complication.
Read the detailed description
Chronic kidney disease (CKD) is a global public health problem. With the decline in renal function, patients with end-stage kidney disease (ESKD) can choose hemodialysis (HD), peritoneal dialysis (PD) or kidney transplantation as renal replacement therapy to improve their quality of life. Globally, HD is still the most important renal replacement therapy.
With the continuous development and optimization of dialysis technology, the survival time of maintenance hemodialysis (MHD) patients is gradually prolonged. However, even in developed countries, the mortality rate of MHD patients remains high. According to data from the United States Renal Data System (USRDS) in 2019, the MHD mortality rate in 2017 was 167 per 1,000 patient-years.
Studies have shown that 30-50% of MHD patients have chronic inflammation state. Persistent inflammation can lead to a variety of complications, especially cardiovascular disease, malnutrition and anemia, thereby increasing the mortality of MHD patients.
Although less than 5% of MHD patients die directly from inflammation, inflammation can interact with a variety of risk factors and has an important impact on the prognosis of MHD patients. Studies have found that inflammation is closely related to high-risk factors of death such as myocardial hypertrophy, ventricular dysfunction, atherosclerosis, protein energy consumption, anemia and renal bone disease .
Therefore, the development of inflammation-related indicators has important clinical value for judging the prognosis of MHD patients and guiding early intervention.
Disturbed functions of polymorphonuclear leukocytes [PMNLs] lead to an enhanced risk of bacterial infections and represent a main cause for the increased risk of morbidity and mortality among CKD patients.
After chemotactic movement to the source of infection, PMNLs take up the invading microorganisms by phagocytosis and kill them with toxic oxygen radicals formed during the oxidative burst and proteolytic enzymes intracellularly released from granula.
Disturbances of any of those crucial PMNL functions increase the risk for bacterial infections. The proneness of CKD patients to infections resulting from decreased phagocytosis is caused by factors such as uremic toxins, iron overload, anemia of renal disease, and dialyzer bioincompatibility.
Neutrophils from HD patients show significantly elevated levels of reactive oxygen species (ROS) production, degranulation, and basal neutrophil extracellular trap (NET) formation, indicating spontaneous activation.
Furthermore, similar to PMNLs from patients with acute infections. Monocytes are bone marrow derived cells that circulate in the blood for 1-3 days before differentiating into tissue macrophages or dendritic cells. In a review in this special issue, Girndt et al.
focuses on the differences of uremic monocytes in the expression of surface molecules, the production of cytokines and mediators, and in their function as compared to monocytes of healthy persons.
Based on their CD14/CD16 expression profile, three distinct populations of monocytes can be distinguished: Mo1 ("classical monocytes" expressing CD14 only), Mo2 ("intermediate monocytes", CD14++/CD16+), and Mo3 ("non-classical monocytes", CD14+/CD16++). The Mo2 population has pronounced pro-inflammatory properties. Their proportion is an important predictor of mortality risk in HD patients [35].
The contribution of monocytes to the dysregulated immune response in uremia can be based on altered features of the individual cells or on a change in the relative numbers of the three different populations. Monocytes play an important role in both innate immunity and antigen presentation for specific cellular immune defense.
In patients with chronic renal failure as well as those treated with maintenance hemodialysis, these cells are largely dysregulated.
Monocytes and macrophages strongly contribute to the pathogenesis of atherosclerosis. These cells invade the vessel wall at sites of endothelial lesions and participate in the formation of foam cells, the deposition of lipids in the intima, and the growth of the atheromatous plaque. Macrophages within vascular plaques express inflammatory markers .
These observations prompted the study of a relationship between the activation of circulating monocytes in the blood of dialysis patients and their risk of atherosclerotic vascular disease. Investigators found many hints that such relation exists. Studies in dialysis patients described correlations between monocyte expression of IL-1 and IL-1RA and cardiovascular events.
The relative frequency of CD14++/16+ Mo2 cells relates to this morbidity in different cohorts with CKD including HD, PD and CKD patients stages 1-5 [37,35,33].
A high expression of ACE on monocytes appears to be associated with cardiovascular disease in HD and PD patients.
In addition, the intensity of monocyte sequestration during a dialysis session as a surrogate for the activation level of this cell type is predictive for cardiovascular events as well.
Since many of the morphological and functional alterations of monocytes are found in both CKD 3-5 and dialysis patients, uremic toxicity may be one of the important causal factors.
However, hemodialysis accentuates some of the monocyte abnormalities. This might be the consequence of inflammatory activation through blood-membrane interactions, and biocompatibility issues may play a role.
Further, dialysis can clear several but not all retention solutes from the blood of uremic patients. It is thus reasonable to test different dialysis modalities (HDF, high cut-off dialysis) if they influence monocyte dysfunction. All these aspects have been addressed in clinical or experimental studies.
Recent studies have found that the ratios of different blood cell components are new inflammatory markers, which have good predictive value in the outcome of CKD, cardiovascular disease, rheumatic disease, etc., including neutrophil-to-lymphocyte ratio (NLR) , monocyte-to-lymphocyte ratio (MLR) , Previous studies have inconsistent conclusions about the predictive value of NLR and MLR on mortality of HD patients. Xiang et al. suggested that higher MLR was a strong and independent predictor of all-cause and cardiovascular mortality and overwhelmed NLR among HD patients .
This study hypothesized that the combination of NLR and MLR could form a new indicator for predicting the mortality of HD patients. Therefore, the study incorporated NLR and MLR into an inflammation scoring system and investigated the value of inflammation score in predicting all-cause and cardiovascular mortality in HD patients.
Besides neutrophil and lymphocytes, monocytes play a key role in inflammation and are well known as a central factor in pathogenesis of atherosclerosis. Patients with ESRD exhibit a general expansion of circulating monocytes with increased basal production of cytokines and reactive oxygen species (ROS), which contribute to the prevailing oxidative stress and systemic inflammation in this population. On the other hand, this kind of spontaneous activation is accompanied by decreased phagocytic capacity of monocytes and impaired antigen presentation capacity, thus leading to defective functions of T and B cells; the impaired expression of co-stimulatory molecules also contributes to this phenomenon. Findings from epidemiological studies indicate that elevated monocyte counts are independently related to all-cause and cardiovascular mortality in HD patients.
- Conditions
- Hemodialysis Complication
- Being tested
- CBC and flow cytometry test for monocyte
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBC and flow cytometry test for monocyteOther
all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
| Study group | Role | What they receive |
|---|---|---|
| 1 | healthy persons to see normal ratio of of neutrophil lymphocyte and monocyte lymphocyte Receives: Other: CBC and flow cytometry test for monocyte | |
| 2 | CKD patients stage (4-5) not on dialysis to see impact of (NLR) and (MLR) as regard inflamation and cardiovascular complications Receives: Other: CBC and flow cytometry test for monocyte | |
| 3 | patients ESRD on maintenance hemodialysis compared with CKD pre dialysis patents and see if hemodialysis is better for removal toxic granules and inflamatory markers caused by CKD Receives: Other: CBC and flow cytometry test for monocyte |
What is being measured
The primary outcome is the main question the study is designed to answer.
Impact of neutrophil lymphocyte and monocyte lymphocyte ratio on chronic kidney disease patients outcome
Neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio in addition to subtypes of monocytes will be measured in healthy persons, CKD patients stage (4-5) and in chronic hemodialysis patients and use it as inflamamtory markers as well as it's a good predictors for cardiovascular complications and what's the impact of it's ratio degree on CKD patients outcome
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2023
- Study start1 Jun 2023 (estimated)
- Primary completionJul 2024 (estimated)
- Study completionOct 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Hemodialysis ComplicationStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abdel rahman Hassan Mohamed, Assiut University
- Investigators
- Ashraf AN el shazly, profeassor, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05887960
- Sponsor's protocol ID
- CKD patients
- Status last verified
- May 2023
- First submitted
- 25 Apr 2023
- Last updated
- 5 Jun 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kim JK, Hong CW, Park MJ, Song YR, Kim HJ, Kim SG. Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. J Immunol Res. 2017;2017:8415179. doi: 10.1155/2017/8415179. Epub 2017 Mar 27.
PubMed 28523279Girndt M, Trojanowicz B, Ulrich C. Monocytes in Uremia. Toxins (Basel). 2020 May 21;12(5):340. doi: 10.3390/toxins12050340.
PubMed 32455723Ramirez R, Carracedo J, Merino A, Soriano S, Ojeda R, Alvarez-Lara MA, Martin-Malo A, Aljama P. CD14+CD16+ monocytes from chronic kidney disease patients exhibit increased adhesion ability to endothelial cells. Contrib Nephrol. 2011;171:57-61. doi: 10.1159/000327134. Epub 2011 May 23.
PubMed 21625090Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan;3(1):19-62. doi: 10.1038/kisup.2012.64. No abstract available.
PubMed 25018975Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33. doi: 10.2215/CJN.00950208. Epub 2008 Aug 13.
PubMed 18701615Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000 Oct;58(4):1758-64. doi: 10.1111/j.1523-1755.2000.00337.x.
PubMed 11012910Mansur A, Mulwande E, Steinau M, Bergmann I, Popov AF, Ghadimi M, Beissbarth T, Bauer M, Hinz J. Chronic kidney disease is associated with a higher 90-day mortality than other chronic medical conditions in patients with sepsis. Sci Rep. 2015 May 21;5:10539. doi: 10.1038/srep10539.
PubMed 25995131James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008 Nov 24;168(21):2333-9. doi: 10.1001/archinte.168.21.2333.
PubMed 19029498Haag-Weber M, Horl WH. Dysfunction of polymorphonuclear leukocytes in uremia. Semin Nephrol. 1996 May;16(3):192-201.
PubMed 8734462
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Neutrophil Lymphocyte and Monocyte Lymphocyte Ratio on Chronic Kidney Disease Patients Outcome
- ClinicalTrials.gov ID
- NCT05887960
- Acronym / sponsor ID
- CKD patients
- Conditions
- Hemodialysis Complication
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jun 2023 (estimated)
- Primary completion
- Jul 2024 (estimated)
- Study completion
- Oct 2024 (estimated)
- First posted
- 5 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to establish NLR, MLR as a good predictors for outcome of CKD including hemodialysis and CKD stage (4-5) patients as regard inflammation, malnutrition and anemia on cardiovascular complication.
Detailed description
Chronic kidney disease (CKD) is a global public health problem. With the decline in renal function, patients with end-stage kidney disease (ESKD) can choose hemodialysis (HD), peritoneal dialysis (PD) or kidney transplantation as renal replacement therapy to improve their quality of life. Globally, HD is still the most important renal replacement therapy.
With the continuous development and optimization of dialysis technology, the survival time of maintenance hemodialysis (MHD) patients is gradually prolonged. However, even in developed countries, the mortality rate of MHD patients remains high. According to data from the United States Renal Data System (USRDS) in 2019, the MHD mortality rate in 2017 was 167 per 1,000 patient-years.
Studies have shown that 30-50% of MHD patients have chronic inflammation state. Persistent inflammation can lead to a variety of complications, especially cardiovascular disease, malnutrition and anemia, thereby increasing the mortality of MHD patients.
Although less than 5% of MHD patients die directly from inflammation, inflammation can interact with a variety of risk factors and has an important impact on the prognosis of MHD patients. Studies have found that inflammation is closely related to high-risk factors of death such as myocardial hypertrophy, ventricular dysfunction, atherosclerosis, protein energy consumption, anemia and renal bone disease .
Therefore, the development of inflammation-related indicators has important clinical value for judging the prognosis of MHD patients and guiding early intervention.
Disturbed functions of polymorphonuclear leukocytes [PMNLs] lead to an enhanced risk of bacterial infections and represent a main cause for the increased risk of morbidity and mortality among CKD patients.
After chemotactic movement to the source of infection, PMNLs take up the invading microorganisms by phagocytosis and kill them with toxic oxygen radicals formed during the oxidative burst and proteolytic enzymes intracellularly released from granula.
Disturbances of any of those crucial PMNL functions increase the risk for bacterial infections. The proneness of CKD patients to infections resulting from decreased phagocytosis is caused by factors such as uremic toxins, iron overload, anemia of renal disease, and dialyzer bioincompatibility.
Neutrophils from HD patients show significantly elevated levels of reactive oxygen species (ROS) production, degranulation, and basal neutrophil extracellular trap (NET) formation, indicating spontaneous activation.
Furthermore, similar to PMNLs from patients with acute infections. Monocytes are bone marrow derived cells that circulate in the blood for 1-3 days before differentiating into tissue macrophages or dendritic cells. In a review in this special issue, Girndt et al.
focuses on the differences of uremic monocytes in the expression of surface molecules, the production of cytokines and mediators, and in their function as compared to monocytes of healthy persons.
Based on their CD14/CD16 expression profile, three distinct populations of monocytes can be distinguished: Mo1 ("classical monocytes" expressing CD14 only), Mo2 ("intermediate monocytes", CD14++/CD16+), and Mo3 ("non-classical monocytes", CD14+/CD16++). The Mo2 population has pronounced pro-inflammatory properties. Their proportion is an important predictor of mortality risk in HD patients [35].
The contribution of monocytes to the dysregulated immune response in uremia can be based on altered features of the individual cells or on a change in the relative numbers of the three different populations. Monocytes play an important role in both innate immunity and antigen presentation for specific cellular immune defense.
In patients with chronic renal failure as well as those treated with maintenance hemodialysis, these cells are largely dysregulated.
Monocytes and macrophages strongly contribute to the pathogenesis of atherosclerosis. These cells invade the vessel wall at sites of endothelial lesions and participate in the formation of foam cells, the deposition of lipids in the intima, and the growth of the atheromatous plaque. Macrophages within vascular plaques express inflammatory markers .
These observations prompted the study of a relationship between the activation of circulating monocytes in the blood of dialysis patients and their risk of atherosclerotic vascular disease. Investigators found many hints that such relation exists. Studies in dialysis patients described correlations between monocyte expression of IL-1 and IL-1RA and cardiovascular events.
The relative frequency of CD14++/16+ Mo2 cells relates to this morbidity in different cohorts with CKD including HD, PD and CKD patients stages 1-5 [37,35,33].
A high expression of ACE on monocytes appears to be associated with cardiovascular disease in HD and PD patients.
In addition, the intensity of monocyte sequestration during a dialysis session as a surrogate for the activation level of this cell type is predictive for cardiovascular events as well.
Since many of the morphological and functional alterations of monocytes are found in both CKD 3-5 and dialysis patients, uremic toxicity may be one of the important causal factors.
However, hemodialysis accentuates some of the monocyte abnormalities. This might be the consequence of inflammatory activation through blood-membrane interactions, and biocompatibility issues may play a role.
Further, dialysis can clear several but not all retention solutes from the blood of uremic patients. It is thus reasonable to test different dialysis modalities (HDF, high cut-off dialysis) if they influence monocyte dysfunction. All these aspects have been addressed in clinical or experimental studies.
Recent studies have found that the ratios of different blood cell components are new inflammatory markers, which have good predictive value in the outcome of CKD, cardiovascular disease, rheumatic disease, etc., including neutrophil-to-lymphocyte ratio (NLR) , monocyte-to-lymphocyte ratio (MLR) , Previous studies have inconsistent conclusions about the predictive value of NLR and MLR on mortality of HD patients. Xiang et al. suggested that higher MLR was a strong and independent predictor of all-cause and cardiovascular mortality and overwhelmed NLR among HD patients .
This study hypothesized that the combination of NLR and MLR could form a new indicator for predicting the mortality of HD patients. Therefore, the study incorporated NLR and MLR into an inflammation scoring system and investigated the value of inflammation score in predicting all-cause and cardiovascular mortality in HD patients.
Besides neutrophil and lymphocytes, monocytes play a key role in inflammation and are well known as a central factor in pathogenesis of atherosclerosis. Patients with ESRD exhibit a general expansion of circulating monocytes with increased basal production of cytokines and reactive oxygen species (ROS), which contribute to the prevailing oxidative stress and systemic inflammation in this population. On the other hand, this kind of spontaneous activation is accompanied by decreased phagocytic capacity of monocytes and impaired antigen presentation capacity, thus leading to defective functions of T and B cells; the impaired expression of co-stimulatory molecules also contributes to this phenomenon. Findings from epidemiological studies indicate that elevated monocyte counts are independently related to all-cause and cardiovascular mortality in HD patients.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 12 Months
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | – | Other: CBC and flow cytometry test for monocytehealthy persons to see normal ratio of of neutrophil lymphocyte and monocyte lymphocyte |
| 2 | – | Other: CBC and flow cytometry test for monocyteCKD patients stage (4-5) not on dialysis to see impact of (NLR) and (MLR) as regard inflamation and cardiovascular complications |
| 3 | – | Other: CBC and flow cytometry test for monocytepatients ESRD on maintenance hemodialysis compared with CKD pre dialysis patents and see if hemodialysis is better for removal toxic granules and inflamatory markers caused by CKD |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- healthy persons as control group patients with chronic kidney disease (CKD) stage 4-5 (not on dialysis) patients ESRD on maintenance hemodialysis
Key inclusion criteria (3 listed)
- - Hemodialysis patients > 18 years
- < 60 years old
- CKD stage (4-5) not on dialysis
Key exclusion criteria (7 listed)
- o Recent acute coronary or cerebrovascular accident
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBC and flow cytometry test for monocyteall groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population | Other | 1, 2, 3 |
Primary outcome
Impact of neutrophil lymphocyte and monocyte lymphocyte ratio on chronic kidney disease patients outcome
Time frame: baseline
Neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio in addition to subtypes of monocytes will be measured in healthy persons, CKD patients stage (4-5) and in chronic hemodialysis patients and use it as inflamamtory markers as well as it's a good predictors for cardiovascular complications and what's the impact of it's ratio degree on CKD patients outcome
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2023.
- Background: PubMed 28523279Kim JK, Hong CW, Park MJ, Song YR, Kim HJ, Kim SG. Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. J Immunol Res. 2017;2017:8415179. doi: 10.1155/2017/8415179. Epub 2017 Mar 27.
- Background: PubMed 32455723Girndt M, Trojanowicz B, Ulrich C. Monocytes in Uremia. Toxins (Basel). 2020 May 21;12(5):340. doi: 10.3390/toxins12050340.
- Results publication: PubMed 21625090Ramirez R, Carracedo J, Merino A, Soriano S, Ojeda R, Alvarez-Lara MA, Martin-Malo A, Aljama P. CD14+CD16+ monocytes from chronic kidney disease patients exhibit increased adhesion ability to endothelial cells. Contrib Nephrol. 2011;171:57-61. doi: 10.1159/000327134. Epub 2011 May 23.
- Results publication: PubMed 25018975Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan;3(1):19-62. doi: 10.1038/kisup.2012.64. No abstract available.
- Results publication: PubMed 18701615Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33. doi: 10.2215/CJN.00950208. Epub 2008 Aug 13.
- Results publication: PubMed 11012910Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000 Oct;58(4):1758-64. doi: 10.1111/j.1523-1755.2000.00337.x.
- Results publication: PubMed 25995131Mansur A, Mulwande E, Steinau M, Bergmann I, Popov AF, Ghadimi M, Beissbarth T, Bauer M, Hinz J. Chronic kidney disease is associated with a higher 90-day mortality than other chronic medical conditions in patients with sepsis. Sci Rep. 2015 May 21;5:10539. doi: 10.1038/srep10539.
- Results publication: PubMed 19029498James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008 Nov 24;168(21):2333-9. doi: 10.1001/archinte.168.21.2333.
- Results publication: PubMed 8734462Haag-Weber M, Horl WH. Dysfunction of polymorphonuclear leukocytes in uremia. Semin Nephrol. 1996 May;16(3):192-201.
- He, T.; Xiong, J.; Huang, Y.; Zheng, C.; Liu, Y.; Bi, X.; Liu, C.; Han, W.; Yang, K.; Xiao, T.; et al. Klotho restrain RIG-1/NF-κB signaling activation and monocyte inflammatory factor release under uremic condition. Life SciLink provided by the sponsor.
Related trials for Hemodialysis Complication
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Not yet recruitingPhase 1/2
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
End Stage Renal Disease, Fatigue
Active, not recruiting
Group Exercise Program Supported By Audiovisual Media During Hemodialysis
Chronic Kidney Failure, Hemodialysis
Active, not recruitingPhase 2
Management of Iron Deficiency Anemia in Hemodialysis Patients
Iron Deficiency Anemia (IDA), ESRD (End Stage Renal Disease)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Samir KM Abdelhamid, professor contact
Ashraf AN el shazly, profeassor principal investigator
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Hemodialysis Complication, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Abdelrahman HA Mohamed, specialist (201009749401, drabdelrahmanmohyeldein@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Impact of neutrophil lymphocyte and monocyte lymphocyte ratio on chronic kidney disease patients outcome (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05887960, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2023.